Precipio Continues to Sign New HemeScreen™ Customers
September 28, 2023 09:00 ET
|
Precipio, Inc.
NEW HAVEN, Conn., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announced that new customer orders are expected to bring total Q4 HemeScreen...
Precipio Reduces Product Revenue Result Needed for Cash Flow Breakeven
September 25, 2023 11:00 ET
|
Precipio, Inc.
NEW HAVEN, Conn., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announced that due to the increased pathology revenue, and the recent...
Precipio Takes Final Step Towards Regaining Nasdaq Compliance
September 21, 2023 09:00 ET
|
Precipio, Inc.
NEW HAVEN, Conn., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) today announced that it has implemented a 1-for-20 reverse stock split of...
Precipio’s Pathology Division Exceeds Breakeven Revenues in August, Four Months Ahead of Plan
September 13, 2023 09:30 ET
|
Precipio, Inc.
NEW HAVEN, Conn., Sept. 13, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announces its Pathology Division has in August exceeded the monthly breakeven...
Precipio Announces Q2-2023 Shareholder Update Call
August 10, 2023 17:00 ET
|
Precipio, Inc.
NEW HAVEN, Conn., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be hosting its Q2-2023 corporate update call on August 17th at 5:00 PM...
Precipio Launches Its Much-Anticipated Quantitative BCR-ABL 2.0 Panel
August 08, 2023 09:00 ET
|
Precipio, Inc.
NEW HAVEN, Conn., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announces the launch of its new quantitative BCR-ABL 2.0 panel, with features...
Precipio’s Operational Efficiency Measures Continue To Reduce Cash Burn And Move The Company Towards Breakeven
August 03, 2023 09:00 ET
|
Precipio, Inc.
NEW HAVEN, Conn., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announces significant reductions in its cash-burn. For the six months ended...
Precipio Unaudited Q2-2023 Revenues Show combined increase of 25% over Q1-2023
August 01, 2023 09:00 ET
|
Precipio, Inc.
NEW HAVEN, Conn., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announces that Q2-2023 revenues have increased to $3.5M in Q2-2023 from $2.8M...
Precipio’s Omnia™ Methodology Enables Diagnosis of MDS With Peripheral Blood Instead of Bone Marrow Biopsy
June 14, 2023 09:49 ET
|
Precipio, Inc.
NEW HAVEN, Conn., June 14, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. leveraged its proprietary HemeScreen Cytopenia panel as part of the diagnostic process for...
Precipio Enters into Collaboration with Prestigious New York-based Institution to Develop Revolutionary Brain Tumor Panel using HemeScreen® Technology
June 13, 2023 09:00 ET
|
Precipio, Inc.
NEW HAVEN, Conn., June 13, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announces that it has entered into a collaboration agreement with a NY-based...